Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 3/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM6 | O15303 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.50 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27909404 | 0.87 | SLC1A1 (0.48) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| Serine SCHEMBL21569404 | 0.87 | SLC1A1 (0.39) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL8637362 | 0.87 | SLC1A1 (0.35) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL1988217 | 0.87 | SLC1A1 (0.35) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL28252494 | 0.86 | SLC1A1 (0.47) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL109454 | 0.86 | SLC1A1 (0.47) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL27903520 | 0.86 | SLC1A1 (0.47) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL9236585 | 0.85 | LTA4H (0.35) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL30859659 | 0.85 | LTA4H (0.35) | SLC1A1GSRSLC1A3SLC1A2GRM8 | |
| SCHEMBL2994699 | 0.85 | SLC1A1 (0.54) | SLC1A1GSRSLC1A3SLC1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005762-A | Polypeptide ligand of targeted scavenger receptor, non-covalent double-targeted molecule and pharmaceutical application thereof | 北京大学 | 2024-05-10 | — | — | CN | claimed |
| CN-102245208-B | immunoglobulin variants and uses thereof | HOFFMAN-LA ROCHE LTD. (CH) | 2016-03-16 | — | — | CN | claimed |
| CN-118339281-A | Engineered enzymes and methods of making and using the same | 基因组股份公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-118005762-A | Polypeptide ligand of targeted scavenger receptor, non-covalent double-targeted molecule and pharmaceutical application thereof | 北京大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-118005762-A | Polypeptide ligand of targeted scavenger receptor, non-covalent double-targeted molecule and pharmaceutical application thereof | 北京大学 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023173261-A1 | LAMB STOMACH EXTRACT VITAMIN B12 PREPARATION PRESCRIPTION AND USES THEREOF FOR TREATING GASTROPATHY | 赵新民 | 2023-09-21 | — | — | WO | disclosed |
| CN-116096869-A | Engineered enzymes and methods of making and using the same | 基因组股份公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4139444-A2 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | Genomatica, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| CN-114558039-A | Application of lactobacillus reuteri and metabolite thereof in preparation of medicine for treating liver cancer | 江苏省肿瘤医院 | 2022-05-31 | — | — | CN | disclosed |
| WO-2021216952-A2 | ENGINEERED ENZYMES AND METHODS OF MAKING AND USING | GENOMATICA, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| CN-113039281-A | Recombinant host cells and methods for producing aspartic acid and beta-alanine | 利戈斯股份有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-7582424-B2 | Accessory cholera enterotoxin and analogs thereof as activators of calcium dependent chloride channel | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-09-01 | — | — | US | disclosed |
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BIOPORT R&D, INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1392317-A4 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA INC (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1392317-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | Antexpharma, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| CN-1433318-A | Vascular endothelial growth factor-2 | HUMAN GENOME SCIENCES INC (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1416354-A | Vascular endothelial growth factor 2 | HUMAN GENOME SCIENCES INC (US) | 2003-05-07 | — | — | CN | disclosed |
| WO-2002100327-A2 | SUBSTITUTED 1-BENZAZEPINES AND DERIVATIVES THEREOF | ANTEXPHARMA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| CN-1193278-A | Chemical compounds | ZENECA LTD (GB) | 1998-09-16 | — | — | CN | disclosed |
| US-4342827-A | GLYCEROL DEHYDROGENASE ENZYMES PRODUCED FROM BACILLUS STEAROTHERMOPHILUS | PUBLIC HEALTH LABORATORY SERVICE, CENTER FOR APPLIED MICROBIOLOGY & RESEARCH (GB) | 1982-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234041-A1 | Substituted 1-benzazepines and derivatives thereof | BAK1, BAD, BAX | SLC1A1 3441/4885GSR 1796/4885SLC1A3 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.